Myeloid cells: unveiling their secrets as biomarkers through next-generation sample preparation

Immuno-Oncology Insights 2024; 5(2), 81

DOI: 10.18609/ioi.2024.012

Published: 25 March
Chyan Ying Ke

Watch the video or view the poster to learn about:

  • The importance of studying myeloid cell biomarkers in developing innovative therapies
  • Studying myeloid cells in different sample types, including whole blood and mouse models
  • Overcoming technical limitations hindering the study of myeloid cells in downstream applications like immune checkpoint blockade research
  • The advantages of Curiox Laminar WashTM technology, including high-throughput capabilities, automation, and improved data quality with smaller sample volumes

Chyan Ting Ke earned her PhD in Medical Engineering and Medical Physics from the Harvard-MIT Division of Health Sciences and Technology in Massachusetts. Her doctoral research focused on investigating the modulation of B-cell adaptive immune responses through the nano-scale organization of antigen presentation on biomaterials. Building on her expertise, she extended her research to integrate biocompatible materials in biological applications at the Singapore Immunology Network, A*Star in Singapore.

With a passion for bioengineering immunology and innovation, Ke currently serves as the Director of Bioapplications at Curiox Biosystems. In this role, she leads the development of enabling research and relevant applications using the Curiox Laminar WashTM technology.